Gilead’s commitment to ending the HIV epidemic

By Deb Telman, executive vice president, corporate affairs and general counsel and Jared Baeten, senior vice president, clinical development, virology therapeutic area head, Gilead Sciences

December 1 2024

Ending HIV is a long and challenging effort, but we are confident that we are heading in the right direction. Many of us remember the dark days of the 1980s and 1990s when HIV ravaged communities from Lagos to Los Angeles. Gilead helped pioneer HIV care by developing options to treat and prevent the disease. Curing HIV remains an ultimate aspiration of Gilead’s HIV research and development efforts, and we are continuing to invest and innovate to further improve treatment and prevention options.

Innovation, though, must extend beyond the lab. We need to commit to eliminating stigma and furthering access in communities that today are most impacted by HIV in the US. That’s why Gilead partners with trusted community organizations to reach those most in need of improved access to care, working together to help remove societal barriers, including HIV stigma and discrimination.

Gilead’s COMPASS Initiative^®, a commitment of over $100 million over 10 years, is one of the largest examples of partnerships in the US that supports organizations working to address the HIV/AIDS epidemic in the South.

Another Gilead charitable program is the TRANScend^® Community Impact Fund, which supports trans-led organizations working to improve the safety, health, and wellness of the transgender community. Gilead is one of the top global supporters of HIV causes.

Our work in the community goes beyond funding. We support community organizations that want to develop programs that help eradicate healthcare gaps and improve patient outcomes, regardless of income, race, ethnicity or sexual orientation. We believe that by working together, we can solve one of the greatest global public health issues of our time and help end the HIV epidemic for everyone, everywhere.

Learn More

COMPASS INITIATIVE, TRANSCEND, GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc. All other marks referenced herein are the property of their respective owners.